Here are the 8-K filings from Renatus Tactical Acquisition Corp I (RTAC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow RTAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RTAC filings page.
Renatus Tactical Acquisition Corp. I appointed Lauren Selig to its Board of Directors on July 21, 2026, effective immediately. She also joined the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, adding over 25 years of experience in entertainment, technology, artificial intelligence, blockchain, and venture investing.
In connection with her appointment, Ms. Selig entered into the company’s standard indemnity agreement and became a signatory to a May 14, 2025 letter agreement, under which she agrees to vote any Class A ordinary shares she holds in favor of the company’s initial business combination and to facilitate liquidation if no business combination occurs within 24 months (or up to 30 months by Board resolution or a longer period approved by shareholders). She will not receive cash compensation or an employment agreement; instead, the sponsor, International SPAC Management Group I LLC, will transfer 50,000 Class B ordinary shares to her as director compensation. The company states there are no family relationships or related party transactions involving Ms. Selig.
Renatus Tactical Acquisition Corp. I reported the resignation of director Matan Fattal, effective June 5, 2026. He also left the Audit, Compensation, and Nominating and Corporate Governance Committees, and his departure was stated not to arise from any dispute with the company or its Board.
The resignation leaves the Audit Committee with fewer than three members and the Board without a majority of independent directors, putting the company out of compliance with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b). Renatus has notified Nasdaq, plans to use the applicable cure periods, and is searching for a new independent director to restore compliance.